TITLE

Cyclacel to speed up Altana drug development

PUB. DATE
May 2005
SOURCE
PharmaWatch: Cancer;May 2005, Vol. 4 Issue 5, p15
SOURCE TYPE
Market Research Report
DOC. TYPE
Article
ABSTRACT
Reports that Cyclacel Group PLC and Altana Pharma AG have signed a research collaboration agreement to identify molecular agents of experimental cancer drugs. Terms of the agreement; Comments of the chief scientist of Cyclacel's Polgen division, David Glover regarding on the discovery of compounds that are active in blocking cells in mitosis by Altana Pharma scientists; Benefits of the technology for Cyclacel in identifying patterns of changes seen in cells.
ACCESSION #
17641778

 

Related Articles

  • Biopharmaceutical company selects high throughput screening system.  // LC-GC Europe;Jan2006, Vol. 19 Issue 1, p10 

    The article reports that Thermo Electron Corp. has entered into a contract with Altana Pharma AG for the installation of a fully integrated ultrahigh throughput screening system. Altana is company involved in the identification of new therapeutic approaches in respiratory inflammation, oncology...

  • Global M&A Heats Up. S. H. // Pharmaceutical Executive;Nov2006, Vol. 26 Issue 11, p31 

    The article reports on the acquisition of several pharmaceutical companies in Europe. The acquired companies includes Serono, Altana Pharma and Schwarz Pharma, which are small, family-controlled companies. Merck KgaA, will become the majority shareholder. Altana, the German company will be...

  • Active Pharmaceutical Ingredient Watch.  // Chemical Market Reporter;6/23/2003, Vol. 263 Issue 25, p15 

    Reports on global developments involving companies in the pharmaceutical industry and trade as of June 23, 2003. Opening of Altana Pharma AG of its Altana Research Institute in Waltham, Massachusetts; Court ruling on the case involving Andrx Corp. and Hoechst Marion Roussel Inc.; Strategic deal...

  • CYCLACEL REPORTS PROGRESS WITH 2ND GENERATION CDK INHIBITOR.  // Worldwide Biotech;Jul2003, Vol. 15 Issue 7, p4 

    Focuses on the cyclin dependent kinase inhibitors for the genes-to-drugs CYC400 rational drug design program of the biopharmaceutical firm Cyclacel Ltd. in Great Britain.

  • Align Acquisition Pads Cyclacel's Resource Base. Young, Donna // BioWorld Today;10/9/2007, Vol. 18 Issue 196, p1 

    This article reports on the acquisition of Align Pharmaceuticals LLC by Cyclacel Pharmaceuticals Inc. in a deal worth up to $3.8 million in cash. Aside from the cash, the deal also involves stock paid to Align Holding LLC. Cyclacel Pharmaceuticals is involved in the development of products for...

  • The Link Between Gross Profitability And Pharmaceutical R&D Spending. Scherer, F.M. // Health Affairs;2001 A Primer, p77 

    Focuses on the link between gross profitability and pharmaceutical research and development (R&D) spending. Development of new products; Expectations of future profit opportunities; Gross margins versus R&D outlays.

  • ICSE Preview One-Stop-Shopping in Pharmaceutical Outsourcing.  // Pharmaceutical Technology Europe;Nov2004 Supplement, p40 

    The article presents information about the exhibition ICSE, that will be organized from December 7-9, 2004 in Brussels, Belgium. During the three days, 20,000 pharmaceutical decision makers from more than 110 countries will be eagerly looking for face-to-face contact with partners who can help...

  • NCL joins Altana for plant-based drugs.  // Chemical Business;Oct2006, Vol. 20 Issue 10, p105 

    The article reports on a collaboration between Altana Pharma AG and the National Chemical Laboratories of India for research on plant-based drugs. Research would include outsourcing for initial phase for identification of lead compound plants used for traditional medicines. The total investment...

  • Hot streak: International acquisitions.  // Pharmaceutical Representative;Nov2006, Vol. 36 Issue 11, p10 

    The article offers news briefs related to world business acquisitions. Merck KGaA has agreed to acquire Geneva-based Serono SA for approximately $13.4 billion and 64.5% of its stocks from the Bertarelli family in Darmstadt, Germany. Denmark-based Nycomed Pharma has agreed to acquire...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics